Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...
7hon MSN
Cipla's Q3FY25 revenue is expected to grow 3.1-7%, with profit estimates ranging from a 2.2% decline to 14% growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback